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Introduction: Loss-of-function TLR7 variants have been recently reported in a small
number of males to underlie strong predisposition to severe COVID-19. We aimed to
determine the presence of these rare variants in young men with severe COVID-19.
Methods: We prospectively studied males between 18 and 50 years-old without
predisposing comorbidities that required at least high-flow nasal oxygen to treat
COVID-19. The coding region of TLR7 was sequenced to assess the presence of
potentially deleterious variants.
Results: TLR7 missense variants were identified in two out of 14 patients (14.3%).
Overall, the median age was 38 (IQR 30-45) years. Both variants were not previously
reported in population control databases and were predicted to be damaging by in silico
predictors. In a 30-year-old patient a maternally inherited variant [c.644A>G;
p.(Asn215Ser)] was identified, co-segregating in his 27-year-old brother who also
contracted severe COVID-19. A second variant [c.2797T>C; p.(Trp933Arg)] was found
in a 28-year-old patient, co-segregating in his 24-year-old brother who developed mild
COVID-19. Functional testing of this variant revealed decreased type I and II interferonorg July 2021 | Volume 12 | Article 7191151
Solanich et al. Rare TLR7 Variants in COVID-19
Frontiers in Immunology | www.frontiersin.responses in peripheral mononuclear blood cells upon stimulation with the TLR7 agonist
imiquimod, confirming a loss-of-function effect.
Conclusions: This study supports a rationale for the genetic screening for TLR7 variants
in young men with severe COVID-19 in the absence of other relevant risk factors. A
diagnosis of TLR7 deficiency could not only inform on treatment options for the patient,
but also enables pre-symptomatic testing of at-risk male relatives with the possibility of
instituting early preventive and therapeutic interventions.Keywords: COVID-19, SARS-CoV-2, host genetics, TLR7, immunodeficiency, genetic screeningINTRODUCTION
A proportion of patients with COVID-19 develop fatal lung
injury and multi-organ failure due to systemic host-immune
inflammatory processes triggered by the viral infection (1).
Advanced age, male sex and chronic disease such as diabetes
and obesity are common in patients with more severe forms of
COVID-19 (2–4). However, these risk factors cannot explain
why critical disease also occurs in young (below 50 years of age)
and apparently healthy individuals.
In the past months, several publications have identified loci
and genes associated with COVID-19 susceptibility for severe
COVID-19 by using comprehensive GWAS studies or genome,
exome or candidate gene analyses (5). However, most of these
susceptibility alleles showed risk values too low (odds ratio <2) to
be regarded as predictive genomic markers. Some of the loci
reported include ABO blood group (6, 7), ACE2 (8), TMPRSS2
(8), several HLA alleles (5, 9), APOE (10), and IFITM3 (11). On
the other hand, rare variants in genes encoding for members of
the type I/III interferon (IFN) pathway showed a higher
estimated risk to severe COVID-19 (12, 13).
In July 2020 rare, deleterious germline variants in the X-
chromosomal Toll-like receptor 7 (TLR7) gene were reported in
young and, otherwise, healthy males with severe COVID-19. In
these two brother pairs, rapid whole-exome sequencing
identified both a maternally inherited 4-nucleotide deletion
[c.2129_2132del; p.(Gln710Argfs*18)] and a missense variant
[c.2383G>T; p.(Val795Phe)]. Both variants were associated with
impaired type I and II IFN responses upon stimulation with the
TLR7 agonist imiquimod, supporting the importance of intact
TLR7 signaling in COVID-19 pathogenesis (13). Most recently
these findings were replicated in an independent Italian cohort
study of males <60 years of age with severe COVID-19 (79 severe
cases versus 77 control cases), showing that 2.1% of severely
affected males harbored deleterious TLR7 variants compared to
none of the asymptomatic participants. These variants were
demonstrated to decrease transcription of type I and II IFN-
related genes in patient peripheral blood mononuclear cells
(PBMC) treated with imiquimod, supporting a loss of function
effect (14).
In follow-up of the recent discovery of TLR7 deficiency in
patients with severe COVID-19, we aimed to prospectively
determine the presence of TLR7 variants in young and
previously healthy men with severe COVID-19.org 2METHODS
This is a joint study performed at the Hospital Universitari de
Bellvitge – IDIBELL, L’Hospitalet de Llobregat, Barcelona, Spain;
and the Radboud University Medical Center, Nijmegen, The
Netherlands and the Erasmus Medical Center, Rotterdam,
The Netherlands.
The Barcelona Cases
FromMarch to July 2020, researchers from Hospital Universitari
de Bellvitge - IDIBELL prospectively collected biological samples
from young patients without comorbidities related to severe
COVID-19. Selection criteria were: 1) patients aged between 18
and 50 years old; 2) absence of known comorbidities associated
with most severe forms of COVID-19 (BMI ≥ 30kg/m2, diabetes
mellitus, hypertension, chronic heart, pulmonary or kidney
disease, or an immunocompromised state); and 3) SARS-CoV-
2 related lung injury requiring high flow oxygen devices or
mechanical ventilation. Ten male patients fulfilled these
selection criteria (Table 1). Eight patients (patients 1-8) were
also evaluated by the COVIDHuman Genetic Effort, although no
pathogenic variants were identified in any of the 13 type I IFN
pathway genes studied (12).
Informed consent was obtained from all patients and relatives,
and the IDIBELL Research Ethics Committee approved this study
(PR152/20). Demographic, epidemiological, laboratory and
clinical data were collected. Treatments specifically used to treat
COVID-19 at any time during admission were also documented.
DNA was isolated from total blood either using a Maxwell
instrument RSC (Promega, Madison, WI, USA) or QIAGEN
Flexigene DNA kit (Qiagen, Germany). Nine PCR primer pairs
(Sigma-Aldrich, MO, USA) were designed to cover the whole
coding region of TLR7 (HGNC ID:15631). PCR was performed
using DreamTaq MasterMix (ThermoFisher Scientific,
Waltham, MA, USA), products were purified using EXO-SAP
(New England Biolabs) and sequenced using the BigDye
Terminator v.3.1 Sequencing Kit (Applied Biosystems, CA,
USA) in an ABI Prism 3730 XL Genetic Analyzer (Applied
Biosystems CA, USA). Primers and PCR conditions are available
upon request. Mutation Surveyor software was used to detect
variants and nomenclature was given according to HGVS
guidelines. All variants identified were submitted to Alamut
Software Suite v2.15.0 (Interactive Biosoftware) to retrieve
population frequency and in silico prediction data.July 2021 | Volume 12 | Article 719115
Solanich et al. Rare TLR7 Variants in COVID-19The Dutch Cases
At the Radboud University Medical Center in Nijmegen and the
Erasmus Medical Center in Rotterdam, the Netherlands, patients
were screened prospectively in a clinical setting from December
2020 to February 2021 with the following criteria: 1) males
between 18 and 40 years of age; 2) absence of comorbidities
known to be associated with severe COVID-19 (BMI ≥ 30kg/m2,
diabetes mellitus, hypertension, chronic heart, pulmonary or
kidney disease, or an immunocompromised state); and 3) PCR-
confirmed SARS-CoV-2 infection requiring high-flow oxygen
therapy or ICU admission. A total of 4 patients (patients 11-14)
fulfilled these inclusion criteria and underwent clinical Sanger
sequencing (patients 11 and 12) or rapid whole-exome
sequencing (patient 13 and 14) to specifically assess genetic
variants in TLR7 (Table 1). Written informed consent was
obtained from patient 13 whose clinical data has been included in
this study. Rapid whole-exome sequencing was performed similar
to previous reports (13). Sanger sequencing was done according to
standard diagnostic procedures at the Department of Human
Genetics, Radboud University Medical Center, protocols and
primers sequences are available upon request.
For patient 13, in whom a rare TLR7 missense variant was
identified, functional testing was performed to evaluate impaired
type I and II IFN responses due to TLR7 loss-of-function, as
described previously (13). In brief, venous blood was drawn and
collected in EDTA tubes (Monject). Subsequently, peripheral
mononuclear blood cells (PBMC) were isolated by density
centrifugation of blood, diluted 1:1 in pyrogen-free saline over
Ficoll-Paque (Pharmacia Biotech). Cells were washed twice in
saline and resuspended in cell culture medium (Roswell Park
Memorial Institute [RPMI] 1640, Gibco) supplemented with
gentamicin, 10 mg/mL; L-glutamine, 10 mM; and pyruvate, 10
mM. PBMC were then stimulated at 5 × 105 cells/well in round-
bottom 96-wells plates (Greiner) for either 4 hours (for
transcription of type I IFN genes) and 7 days [for production
of the type II IFN, (IFNg)] in the presence of 10% human pool
serum at 37°C and 5% carbon dioxide, in two separateFrontiers in Immunology | www.frontiersin.org 3experiments. Apart from a negative medium (RPMI) control,
the TLR7 agonist imiquimod (imidazoquinoline compound,
Invivogen) was used at a concentration of 5 mg/mL. After the 4
hour incubation period, the supernatants were discarded and
the remaining cell pellets were resuspended in RLT buffer
(Qiagen) and snap frozen to be stored at −80°C until
processing for RNA isolation. In addition, after the 7 day
incubation and a centrifugation step, supernatants were
collected and stored at −20°C until measured using enzyme-
linked immunosorbent assay in case of the 7 day timepoint.RESULTS
TLR7 Sequencing Results
A total of 14 patients were included, with a median age of 38
(IQR 30-45) years. Putative deleterious TLR7 missense variants
were identified in two patients (patient 10 and 13). Both variants,
c.644A>G; p.(Asn215Ser) in patient 10 and c.2797T>C;
p.(Trp933Arg) in patient 13, were not previously reported in
our in-house databases nor in the population database gnomAD
(15). The p.(Asn215Ser) variant affects a highly conserved
nucleotide and amino acid in the TLR7 leucine-rich region
domain and is predicted damaging or possibly damaging by in
silico software (Table S1). The p.(Trp933Arg) variant is also
located at an evolutionarily highly conserved position within the
TIR domain, important for downstream signaling via adapter
proteins, and is considered deleterious by in silico effect
predictors (Table S1). These TLR7 variants and other
previously reported variants in COVID-19 patients are shown
schematically in Figure 1.
Patients’ Characteristics
Patient 10 (family 1, proband) was a 30-year-old man from Latin
origin (Dominican Republic) with no general risk factors
predisposing to severe COVID-19. He developed pneumoniaTABLE 1 | Demographic and clinical findings of investigated patients.
Patient Sequencing Gender Age (y) Ethnicity Comorbidities ARDSa ICU ECMO
1 Sanger M 31 Caucasian no yes no no
2 Sanger M 44 Caucasian no yes yes no
3 Sanger M 41 Latin (Venezuela) no yes yes yes
4 Sanger M 40 Caucasian no yes yes no
5 Sanger M 50 Latin (Peru) no yes yes no
6 Sanger M 48 Caucasian no yes yes no
7 Sanger M 45 Latin (Peru) no yes yes no
8 Sanger M 31 Latin (Honduras) no yes yes no
9 Sanger M 47 Latin (Peru) no yes no no
10b Sanger M 30 Latin (Dominican Republic) no yes yes no
11 Sanger M 21 Caucasian no yes yes no
12 Sanger M 36 Caucasian no yes yes no
13b WES M 28 Caucasian no yes yes no
14 WES M 31 Caucasian no yes no noJuly 2021 | Volume 12 | ArticleARDS, acute respiratory distress syndrome; ECMO, extracorporeal membrane oxygenation; ICU, intensive care unit; F, female; M, male; WES, whole-exome sequencing; Y, years.
aARDS Definition Task Force. Acute Respiratory Distress Syndrome - The Berlin Definition. JAMA. 2012;307(23):2526-2533. doi:10.1001/jama.2012.5669.
bPatients 10 and 13 resulted carriers of TLR7 variants and belong to family 1 and 2, respectively.719115
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scan and fulfilled the criteria of acute respiratory distress
syndrome (ARDS) secondary to PCR-proven COVID-19
(Table 2). The patient received antiviral treatment with
remdesivir and immunosuppressive therapy with dexamethasone.
Due to respiratory insufficiency, the patient was intubated and
admitted in ICU.Thepatientwas successfully extubated after 4days
ofmechanical ventilationandwasdischarged fromICUafter 6days.
After the identification of the TLR7:p.(Asn215Ser) variant in the
patient, segregation analysis confirmed co-segregation in both his
brother and mother, in hemi- and heterozygous state, respectively
(Figure 1). The eldest brother lives in the Dominican Republic and
was therefore not available for testing. According to relatives, there
is no evidence that he has been infected with SARS-CoV-2. The
youngest brother had no previous medical history but also
contracted severe COVID-19, requiring mechanical ventilation
and ICU admission at another hospital (Table 2). These brothers
therefore represent the third brother pair with severe COVID-19,
following the initial report (13). The 65 year-old mother suffered
from obesity, dyslipidemia, type 2 diabetes and hypertension, and
was also admitted in ICUdue tocritical respiratory failure causedby
COVID-19. She was discharged from the ICU 16 days after
admission. Main demographic, clinical, laboratory, andFrontiers in Immunology | www.frontiersin.org 4radiological findings of the three relatives are summarized
in Table 2.
Patient 13 (family 2, proband) was a 28-year-old male from
Caucasian origin (The Netherlands) without previous medical
history or comorbidities. The patient complained of progressive
dyspnea and shortness of breath. Following rapid clinical
deterioration and respiratory insufficiency, the patient was
intubated and hospitalized in ICU at a peripheral hospital. A
CT-scan showed multiple diffuse ground-glass opacities and
consolidations in all lung segments, meeting the criteria for
ARDS. Treatment consisted of mechanical ventilation with
prone positioning, intravenous dexamethasone, and the
antibiotics ceftriaxone and ciprofloxacin. Despite this
therapeutic regiment, the patient’s condition further
deteriorated and he was referred to the Erasmus Medical
Center for possible ECMO treatment. However, with
continuing prone positioning he gradually improved before
ECMO was required. A repeated CT scan also showed
subsegmental pulmonary embolisms for which intravenous
heparin was started. In the following weeks, the patient
gradually recovered and was successfully extubated and
eventually discharged from the hospital. The patients’ first-
degree family contracted COVID-19 at the time the patientA
B
FIGURE 1 | (A) displays pedigrees of families 1 (patient 10) and 2 (patient 13) with segregation analysis. (B) shows schematic representation of TLR7 (HGNC
ID:15631) variants reported to date in severely affected COVID-19 cases. Variants in cDNA (top) and protein (bottom). Color code: orange, variants found in the
present series; blue, previously reported in van der Made (13); black, previously reported in Fallerini (14). Shape code: circle, missense variants; square, frameshift
variants. Line code: single, reported in one case; double, reported in 2 cases.July 2021 | Volume 12 | Article 719115
TABLE 2 | Demographic, clinical, laboratory, and radiological findings of investigated patients.
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Date of hospitalization July/2020 March/2020 August/2020
Age, y 30 27 65
Sex Male Male Female
Medical history None None Obesity, dyslipidemia,
hypertension,
type 2 diabetes,
Clinical characteristics at presentation
Time from symptom onset to hospitalization, d 7 6 12
Symptoms at disease onset Dyspnea, cough, fever, myalgia Dyspnea, cough, fever, headache Dyspnea, cough, fever, myalgia
Imaging features (CT scan) Bilateral pulmonary consolidations Bilateral pulmonary consolidations Bilateral pulmonary consolidatio
ICU admission
Time from symptom onset to ICU admission, d 8 7 12
Medical reason for ICU admission Respiratory insufficiency Respiratory insufficiency Respiratory insufficiency
Disease severity status on admission, SOFA score* 3 3 4
Laboratory findings at ICU admission
Chemistry
Alanine aminotransferase, U/L 135 14 23.5
Albumin, g/L 37 31 28.1
Alkaline phosphatase, U/L 131 66 84.0
Aspartate aminotransferase, U/L 92 22 73.8
Cardiac troponin, high sensitivity, ng/L NA 7 NA
Creatine kinase, U/L 51 35 180
Creatinine, mmol/L 60 57 57.1
eGFR, mL/min/1.73 m2 >90 >90 >90
g-Glutamyltransferase, U/L 243 27 34.8
Lactate dehydrogenase, U/L 381 432 1088.4
Blood count
Hemoglobin, g/L 112 114 110
Lymphocyte count, ×109/L 1.8 1.47 2.19
White blood cell count, ×109/L 18 10.7 14.74
Platelet count, ×109/L 385 408 416
Coagulation
Activated partial thromboplastin time ratio 0.95 0.98 1.00
D-dimer, ng/mL <250 463 2400
Fibrinogen, g/L > 7 > 7 5.5
Prothrombin time ratio 1.38 1.32 1.10
Inflammatory markers
C-reactive protein, mg/L 346.6 267 203.98
Ferritin, mg/L 1957.6 920 384.9
Procalcitonin, mg/L 0.28 NA 0.1
IL-6, ng/L 48.4 1.5 24n
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Frontiers in Immunology | www.frontiersin.org 6developed symptoms, including his 24-year-old brother, who
had only minor symptoms but was shown to be a carrier of the
TLR7 variant (Figure 2B). Information on the exact SARS-CoV-
2 viral titers during infections were unavailable. In addition, two
male cousins, sons of a maternal aunt, were proven to be carriers of
this variant. These individuals had not contracted (symptomatic)
COVID-19. Based on the TLR7 variant carriership, these individuals
were fast-tracked for early vaccination.
Functional Testing in Primary
Immune Cells
In PBMC isolated from patient 13, the type I and II IFN
responses were evaluated upon stimulation with the TLR7
agonist imiquimod, in order to assess the functional impact
of the p.(Trp933Arg) variant. It was shown that TLR7
stimulation in the patient resulted in a defective upregulation
of TLR7 mRNA expression, as well as that of the type I IFN-
related genes involved in the TLR7 pathway IRF7, IFNB1 and
ISG15, as compared to a healthy male control (Figures 2A, B).
Expression of IRF3, a transcription factor that is induced by
TLR3 and not TLR7, showed a modest increase of almost 1.7
fold in the patient, but was not induced in the healthy control.
Moreover, the production of IFNg upon exposure with
imiquimod was deficient in the patient, compared to two
healthy male controls (Figure 2C).DISCUSSION
In this cohort of young males affected with severe COVID-19
rare TLR7 variants were prospectively identified in 2 out of 14
cases (14.3%). In 10 cases from Spain, one patient was shown to
carry a new missense variant [c.644A>G; p.(Asn215Ser)]. The
variant was predicted as damaging by in silico programs and
segregated in a brother who also contracted severe COVID-19. In
addition, four Dutch cases were studied, leading to the
identification of another patient with a novel, unique missense
variant [c.2797T>C; p.(Trp933Arg)] located in the highly
conserved TIR domain. Functional analysis of the latter variant
demonstrated defective type I and II IFN responses, similar to
those documented in the previous reports (13, 14).
A role for the TLR7 receptor has been described in the host
defense against single-stranded RNA viruses as well as in the
pathogenesis of autoimmune disease such as SLE (16). However,
no human mutations in TLR7 had been reported before the
SARS-CoV-2 pandemic. It should be noted that complete TLR7
deficiency is estimated to be extremely rare, because endosomal
TLRs (TLR3, TLR7, TLR8, and TLR9) play an essential, non-
redundant biological role in host survival (17, 18). Therefore,
these rare TLR7 variants are unlikely to be an explanation for
severe COVID-19 in the general population. Distinct from the
previously published studies that have identified (enrichment of)
rare TLR7 variants in severe COVID-19 who were 1) males <35
years of age without comorbidities (13), 2) males <60 years of age
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Solanich et al. Rare TLR7 Variants in COVID-19patients (19), in this study we have selected males <50 years of
age without comorbidities predisposing to severe COVID-19.
Despite the small cohort, the yield of TLR7 variants was
unexpectedly high (14.3%) encouraging that screening for
TLR7 rare variants in severely affected men may be fruitful.
Elderly individuals also carry rare, loss of function TLR7 variants
(14), but are more difficult to identify due to other predisposing
general risk factors for severe disease in people of advanced age.
Therefore, we suggest the following screening criteria: young
men (<50 year of age) suffering from severe COVID-19 requiring
at least high-flow oxygen therapy, and who were previouslyFrontiers in Immunology | www.frontiersin.org 7healthy. Affected young brother pairs, as well as pedigrees
suggestive for X-linked segregation, should be further prioritized.
We furthermore hypothesize that some rare variants
compromise essential functional domains in TLR7 and lead to
full TLR7 deficiency (20), while other less rare variants might
lead only to a partial TLR7 deficiency, and consequently impact a
larger group of individuals, but exert a lower relative risk to
develop severe COVID-19. Accordingly, these low effect size
genetic variants in TLR7 have been proposed as a possible
explanation of the male sex bias in COVID-19 severity because
of its localization on the X chromosome and well-establishedA
B
C
FIGURE 2 | Assessment of ex vivo/in vitro type I and II interferon responses in peripheral blood mononuclear cells. In all panels, patient 13 is indicated in red and
the healthy controls in black. (A) shows the fold change in TLR7 mRNA expression in patient 13 and a healthy male control after stimulation for 4 hours with the
TLR7 agonist imiquimod, compared to the negative medium control RPMI. (B) displays the fold change in mRNA expression of type I IFN–related genes IRF3, IRF7,
IFNB1 and ISG15 induced by imiquimod as compared to RPMI. (C) shows the production of IFN-g production after imiquimod stimulation for 7 days as compared
with unstimulated control cells (RPMI) from patient 13 and two healthy male controls. The dotted line indicates the assay’s detection limit. Abbreviations: IRF3,
interferon regulatory factor 3; IRF7, interferon regulatory factor 7; ISG15, interferon-stimulated gene 15; and IFNB1, interferon beta 1.July 2021 | Volume 12 | Article 719115
Solanich et al. Rare TLR7 Variants in COVID-19function in innate immunity (21). Furthermore, it is possible, but
only speculative, that the addition of factors that deteriorate
TLR7 function [e.g. circulating 25-hydroxy vitamin D [25OHD]
levels decline with age (22) and may be accompanied by a lower
TLR7 expression and defective function (23)] in patients with
these low effect variants may be a common cause of progression
to the most severe stages of COVID-19 in male. The same
speculative hypothesis could be applicable to other genes
involved in immune response regulation after SARS-CoV-2
infection (4, 24).
Strong host genetic factors that confer an increased risk to
develop severe COVID-19 might serve as genomic biomarkers,
along with other factors, that could be used for early diagnosis
and preventative measures, and could allow the identification of
possible molecular targets for treatment. In this respect, there
would be a strong argument to offer hemizygous TLR7 deficient
males that have not had COVID-19 direct access to early
vaccination as an effective preventative measure, similar to
other patients with primary immunodeficiencies. This option
has indeed been offered to the hemizygous carriers in the family
of patient 13. Although no data is yet available to support specific
management of TLR7 deficiency or the at-risk hemizygous
carriers, early hospitalization and IFN-based therapies in
inborn errors of IFN signaling form rational treatment options
(18, 25).
This study has several limitations. First, no biological samples
were available to functionally validate the pathogenicity of the
p.(Asn215Ser) variant and therefore the functional impact of this
variant remains unknown. Nevertheless, the absence of this
variant in population databases, the high prediction scores for
pathogenicity and the general scarcity of rare variants in TLR7
(13) suggest this finding is unlikely due to chance. Second, the
TLR7 variant identified in patient 13 segregates in a brother who
only experienced mild COVID-19. There are some explanations
that may explain why a pathogenic variant in TLR7 does not
become fully penetrant, since protection against SARS-CoV-2
depends on other genetic and environmental factors (e.g.
exposure to a lower initial viral load, previous exposure to
common cold coronaviruses) (26). Moreover, TLR7 function
might be specifically influenced by epidemiological factors and
certain comorbidities (e.g. 25OHD). Thirdly, the size of this
study does not permit to draw any firm conclusions on the
prevalence of loss of function TLR7 variants in males with severe
COVID-19. Hence, larger cohort studies are required. Most
recently, in pan-ancestry whole-exome sequencing data of
586,157 individuals, encompassing 20.592 patients who
contracted COVID-19 and 1.266 of those who had severe
disease, TLR7 was the only gene in which the burden of rare
variants was significantly increased among patients with severe
COVID-19, using a less conservative significance threshold [OR
4.53 (2.64, 7.77)] (19). This is one of the few occasions in which a
Mendelian disease gene is replicated through the use of an
association study, even without stratifying for male gender or
younger age.
In summary, we have identified two novel germline variants
in the X chromosomal TLR7 that likely lead to TLR7 deficiency,Frontiers in Immunology | www.frontiersin.org 8which is further corroborated by impaired type I and II IFN
responses in the patient with the p.(Trp933Arg) variant. These
findings reinforce the notion that TLR7 plays a critical role in the
recognition of SARS-CoV-2 and the subsequent initiation of an
early antiviral immune response that could prevent the
development of severe COVID-19. More importantly, a better
understanding of strong genetic factors predisposing to severe
COVID-19 may help physicians to identify patients at risk. We
therefore propose clinical screening criteria for the identification
of TLR7 variants in male patients with severe COVID-19. This
could not only enable targeted therapeutic management of the
patient, but could also offer relatives the option of pre-
symptomatic testing and by extension preventative measures
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